On Apr. 13, 2020, Blackstone and Alnylam Pharma announced a broad strategic collaboration under which Blackstone will provide up to $2 billion to support Alnylam’s advancement of innovative RNA interference (RNAi) medicines that have the potential to transform the lives of patients suffering from a range of debilitating diseases.

The transaction incuded $1 billion in committed payments, led by Blackstone Life Sciences, to acquire 50 percent of Alnylam’s royalties and commercial milestones for inclisiran; a $100 million purchase of Alnylam common stock; $750 million in loan and $150 million in a LOI.